Dr. Pilar Sanchez

Dr Pilar Sanchez

Office

Madrid

Region Covered

Spain

Email

psanchez@ppi.consulting


Pilar is a board director for PPi  Healthcare Consulting since its inception in 2002.

She is the PPi Healthcare representative for Spain.

After working for the pharmaceutical industry, she started her company providing regulatory affairs and pricing, reimbursement and market access services. Pilar has 25+ years of experience in understanding the issues particular to the Spanish market.

Pilar is a qualified pharmacist and owns a Master of Pharmacoeconomics and Health Economy.

About

TESTIMONIALS

With their depth of market access experience across the EU, Adam Barak and his team at PPi Healthcare are well-positioned to provide timely, insightful guidance on pricing and reimbursement. ProMetic’s global strategic launch plans involving ultra-orphan therapies, have been greatly enhanced by our collaboration with PPi.

Kristine Dorward, Director, Marketing & Business Development, ProMetic Life Sciences Inc.

I want to let you know that the feedback from my colleagues after your presentation was that they are impressed by the amount of information that you have gathered within the research within such a short period.

Ramona Schmid, Global Market Access, Pricing and Reimbursement Manager, HRA Pharma

I have worked with PPi on several projects and I will work with them again. The first project was a European pricing study for an orphan product. Having already completed one study with a competitor, I found the PPi team to be particularly insightful, having taken the time to completely understand this complex project. Recently I completed an assessment to inform the collection of pharmacoeconomic data in a clinical study in the US and Europe. The team again were very insightful and we had unexpected value-added when we found a member of the PPi had been involved in the pricing and reimbursement activities relating to one of our comparables. Great team, great results!

Thomas W. MacAllister JD, PhD,Vice President of R&D and General Counsel, Remedy Pharmaceuticals